NASDAQ:GEVA (GEVA) (GEVA) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free GEVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (GEVA) alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About (GEVA) Stock (NASDAQ:GEVA)Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company’s other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. GEVA Stock News HeadlinesApril 23, 2024 | msn.comWhy You Should See Newtown, a New Play About the Sandy Hook ShootingApril 22, 2024 | msn.comBacteria in the intestine that change in response to inflammation could have an impact on our immune systemApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 20, 2024 | msn.comGeva Theatre presents "Newtown"April 18, 2024 | msn.com'We need to adapt better on the court' - Leeds Rhinos Netball need to bounce back at Strathclyde SirensApril 17, 2024 | msn.comAfter things 'went sideways' in 2023, Shimona Jok is grateful for another Super Netball opportunityApril 16, 2024 | msn.comTechnology behind SA’s leading banking appsApril 13, 2024 | msn.comTechnion team discovers important adaptive strategy of the microbiome, impacting immune systemApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 13, 2024 | msn.comZoe Davies slowly introducing winning Australian mindset to Leeds Rhinos NetballApril 13, 2024 | msn.comRochester nonprofit takes advantage of Total Sports Experience during drastic weather changesApril 12, 2024 | msn.com‘Newtown’ play to make world premiere at Geva TheatreApril 10, 2024 | theglobeandmail.comUnder constant threat of Hezbollah fire, residents of Israeli town welcome wider war as path to peaceApril 10, 2024 | msn.comIntestinal bacteria changes in reaction to inflammation, effecting immune system, study findsApril 8, 2024 | msn.comSuper Netball Season Preview: Thunderbirds, Giants, Mavericks, VixensApril 4, 2024 | msn.comCEO of organization that has helped 300,000 Ukrainian refugees to speak in RochesterMarch 30, 2024 | bbc.comWatch: Netball Super League - Cardiff Dragons v London PulseMarch 29, 2024 | msn.comBank lends hand to vulnerable children in a Dar orphanageMarch 29, 2024 | msn.comReview: Theater Latte Da's 'Color Purple' marries brutality with artistryMarch 27, 2024 | msn.com'Consistency and composure' needed of Leeds Rhinos Netball or season will be over, warns Liana LeotaMarch 27, 2024 | msn.comGeva Theatre reveals line-up for the 2024/2025 seasonMarch 26, 2024 | msn.comArab citizens of Israel: Between repression and hopeMarch 25, 2024 | msn.comGeva Theatre announces 2024-25 season lineupMarch 25, 2024 | msn.comLarge language models use a surprisingly simple mechanism to retrieve some stored knowledgeMarch 22, 2024 | msn.comLeeds Rhinos Netball need to play to Joyce Mvula's strengths more, says Liana LeotaMarch 22, 2024 | msn.comGeva Theatre invites the public to 2024-25 season unveilingMarch 16, 2024 | bbc.comWatch: Netball Super League - Loughborough Lightning v Leeds RhinosSee More Headlines Receive GEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (GEVA) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2015Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:GEVA CUSIP87159A10 CIK911326 Webwww.synageva.com Phone+1-781-3579900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report GEVA Stock Analysis - Frequently Asked Questions How were (GEVA)'s earnings last quarter? (GEVA) (NASDAQ:GEVA) posted its earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analysts' expectations of $1.25 million. What other stocks do shareholders of (GEVA) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (GEVA) investors own include AutoZone (AZO), Intuitive Surgical (ISRG), U-Haul (UHAL), Regeneron Pharmaceuticals (REGN), Netflix (NFLX), AT&T (T), Novavax (NVAX), Ur-Energy (URG), Biogen (BIIB) and BioMarin Pharmaceutical (BMRN). This page (NASDAQ:GEVA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (GEVA) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
